Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B G Szczepankiewicz

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Topics in Medicinal Chemistry|December 17, 2008
Sirtuin modulators: targets for metabolic diseases and beyondB G Szczepankiewicz, P Y Ng
Current Medicinal Chemistry|February 7, 2003
Prospects for pharmacologic inhibition of hepatic glucose productionR Kurukulasuriya, J T Link, D J Madar, et al.
Current Medicinal Chemistry|February 7, 2003
Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose productionR Kurukulasuriya, J T Link, D J Madar, et al.
Life Sciences|November 24, 1998
The effects of diminishing albumin binding to some Endothelin receptor antagonistsB G Szczepankiewicz, R B Bal, T W von Geldern, et al.
Journal of Medicinal Chemistry|September 10, 1999
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivityT W von Geldern, A S Tasker, B K Sorensen, et al.
Journal of Medicinal Chemistry|August 14, 1998
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546)G Liu, K J Henry, B G Szczepankiewicz, et al.
Journal of Medicinal Chemistry|December 1, 2001
New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor modelsB G Szczepankiewicz, G Liu, H S Jae, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Topics in Medicinal Chemistry|December 17, 2008
Sirtuin modulators: targets for metabolic diseases and beyondB G Szczepankiewicz, P Y Ng
Current Medicinal Chemistry|February 7, 2003
Prospects for pharmacologic inhibition of hepatic glucose productionR Kurukulasuriya, J T Link, D J Madar, et al.
Current Medicinal Chemistry|February 7, 2003
Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose productionR Kurukulasuriya, J T Link, D J Madar, et al.
Life Sciences|November 24, 1998
The effects of diminishing albumin binding to some Endothelin receptor antagonistsB G Szczepankiewicz, R B Bal, T W von Geldern, et al.
Journal of Medicinal Chemistry|September 10, 1999
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivityT W von Geldern, A S Tasker, B K Sorensen, et al.
Journal of Medicinal Chemistry|August 14, 1998
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546)G Liu, K J Henry, B G Szczepankiewicz, et al.
Journal of Medicinal Chemistry|December 1, 2001
New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor modelsB G Szczepankiewicz, G Liu, H S Jae, et al.
Pageof 1